WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US FDA panel takes up GRAIL's Galleri cancer screening PMA on September 23 FDA folds the human factors guidance into eSTAR 7.1 and widens PreSTAR to five more meeting types AVAVA raises $45M with a third of it in debt from its lead investor UpFront Diagnostics wins a CE mark for a 10-minute stroke blood test Ambu pays $45M upfront for TIMS Medical and about 7,000 US hospital installs Citi downgrades Boston Scientific over the cyberattack recovery Autonomix puts Medtronic's former chief regulatory counsel on its board FDA calls the NOxBOXi oxygen leak fix a Class II correction, three years after a Class I recall FDA approves Cordis Selution SLR, the first sirolimus drug-eluting balloon sold in the US FDA panel takes up GRAIL's Galleri cancer screening PMA on September 23 FDA folds the human factors guidance into eSTAR 7.1 and widens PreSTAR to five more meeting types AVAVA raises $45M with a third of it in debt from its lead investor UpFront Diagnostics wins a CE mark for a 10-minute stroke blood test Ambu pays $45M upfront for TIMS Medical and about 7,000 US hospital installs Citi downgrades Boston Scientific over the cyberattack recovery Autonomix puts Medtronic's former chief regulatory counsel on its board FDA calls the NOxBOXi oxygen leak fix a Class II correction, three years after a Class I recall

Acquisition

Ambu pays $45M upfront for TIMS Medical and about 7,000 US hospital installs

MedDevice Startups Staff · Sep 15 · 2 min read · Via Life Science Focus

Ambu agreed to buy TIMS Medical for $45 million in cash, with up to $20 million more tied to milestones. The deal is worth up to $65 million.

TIMS Medical is the finished-device division of Foresight Imaging, a Chelmsford, Massachusetts company founded in 1999. The division started in 2004 and sells imaging capture, connectivity and reporting systems for endoscopy, modified barium swallow studies and fiberoptic endoscopic evaluation of swallowing. Ambu puts the installed base at roughly 7,000 US hospital sites.

Ambu says the purchase feeds its EndoIntelligence agenda, which pairs its single-use endoscopes with software and AI across endoscopy applications. The Danish company left its 2025/26 outlook unchanged after the announcement.

Ambu is paying for the installed base more than the hardware. Seven thousand sites already run this software inside their imaging workflow, and Ambu scopes now have somewhere to plug in.

Questions & Answers

How much is Ambu paying for TIMS Medical?

Ambu is paying $45 million in cash upfront for TIMS Medical, with up to $20 million more tied to milestones. The deal is worth up to $65 million and was announced in September 2026.

What does TIMS Medical do?

TIMS Medical is the finished-device division of Foresight Imaging, a Chelmsford, Massachusetts company founded in 1999. It sells imaging capture, connectivity and reporting systems used in endoscopy, modified barium swallow studies and fiberoptic endoscopic evaluation of swallowing.

Why is Ambu buying TIMS Medical?

Ambu says the purchase feeds its EndoIntelligence platform, which pairs single-use endoscopes with software and AI. The acquisition also brings roughly 7,000 installations across US hospitals. Ambu left its 2025/26 guidance unchanged.

← Back to M&A